Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HECN30227 in Healthy Volunteers and Chronic Hepatitis B Patients
NCT07771140Phase 1Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HECN30227 in hepatitis B (HBV) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Number of Adverse Events In Part 1 at 85 days and Number of Adverse Events In Part 2 at 169 days. Started Dec 2025; status: recruiting.
02
Drugs
HECN30227
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07771140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771140.